Empowered Patient Podcast

Michael Tkach, Chief Operating Officer and Chief Behavioral Health Officer, Affinity describes a variety of models for large-scale population healthcare management for Return to Work/Stay at Work in this time of COVID-19. With continuous monitoring, testing and data analysis, risk assessment is being used to keep companies aware of adherence to guidelines and regulations and the physical and mental health of their employees. In addition, Affinity is rolling out pop-up COVID Clinics in business settings and in communities with limited healthcare options to provide testing and COVID related information.

@AffinityRTW #MentalHealthMonday #COVID19Testing #workplacetesting #returntowork #WorkplaceMentalHealth #humanresources #mentalhealth

AffinityReturntoWork.com/rtw

Listen to the podcast here

Michael Tkach, Chief Operating Officer and Chief Behavioral Health Officer, Affinity describes a variety of models for large-scale population healthcare management for Return to Work/Stay at Work in this time of COVID-19. With continuous monitoring, testing and data analysis, risk assessment is being used to keep companies aware of adherence to guidelines and regulations and the physical and mental health of their employees. In addition, Affinity is rolling out pop-up COVID Clinics in business settings and in communities with limited healthcare options to provide testing and COVID related information.

@AffinityRTW #MentalHealthMonday #COVID19Testing #workplacetesting #returntowork #WorkplaceMentalHealth #humanresources #mentalhealth

AffinityReturntoWork.com/rtw

Download the transcript here

Dr. Greg Rippon, Vice President and Chief Medical Partner of Neurology, Genentech shines light on SMA, spinal muscular atrophy, a severe inherited progressive neuromuscular disease and one of the most common rare diseases affecting babies. With the introduction of Evrysdi to the treatment options for SMA, an oral treatment is being tested to increase the production of the functional survival motor neuron protein and thus benefit patients in their motor functioning.

@genentech #genentech #SMA #SpinalMuscularAtrophy #Evrysdi #raredisease

GENE.com

Listen to the podcast here.

Dr. Greg Rippon, Vice President and Chief Medical Partner of Neurology, Genentech shines light on SMA, spinal muscular atrophy, a severe inherited progressive neuromuscular disease and one of the most common rare diseases affecting babies. With the introduction of Evrysdi to the treatment options for SMA, an oral treatment is being tested to increase the production of the functional survival motor neuron protein and thus benefit patients in their motor functioning.

@genentech #genentech #SMA #SpinalMuscularAtrophy #Evrysdi #raredisease

GENE.com

Download the transcript here.

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order to modulate these channels to help treat diseases that have a significant inflammatory component. Initially developed drugs for acute pancreatitis targeting both the pancreas and the lung. Now conducting large trial in patients with severe and critical COVID-19 as many of the mechanisms that are shared in the development of lung disease with COVID-19 are shared with acute pancreatitis. Strong evidence that their drug Auxora might be effective for a variety of disorders that cause lung injury.

@CalciMedicaInc #COVID19 #CriticalCare #inflammatorydiseases #pancreatitis #CRACChannelinhibitors

CalciMedica.com

Listen to the podcast here.

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order to modulate these channels to help treat diseases that have a significant inflammatory component. Initially developed drugs for acute pancreatitis targeting both the pancreas and the lung. Now conducting large trial in patients with severe and critical COVID-19 as many of the mechanisms that are shared in the development of lung disease with COVID-19 are shared with acute pancreatitis. Strong evidence that their drug Auxora might be effective for a variety of disorders that cause lung injury.

@CalciMedicaInc #COVID19 #CriticalCare #inflammatorydiseases #pancreatitis #CRACChannelinhibitors

CalciMedica.com

Download the transcript here

Dr. Aaron Koenig, Senior Medical Director and Mike Quirk, Vice President of pharmacology Sage Therapeutics focus on disorders of cognition and diseases that reflect determinants of impaired cognition such as Alzheimer's, Parkinson's and Huntington's. Their drug Sage-718, a novel mechanism of action, targets a protein in the brain, the NMDA receptor, thought to be the brain's coincidence detector designed to link together information that flows from different neural pathways and perhaps correct some of the symptoms causing functional impairment.

@SageBiotech #Alzheimers #Parkinsons #Huntingtons #executivefunction #cognition #neurodegeneration

SageRx.com

Listen to the podcast here

Dr. Aaron Koenig, Senior Medical Director and Mike Quirk, Vice President of pharmacology Sage Therapeutics focus on disorders of cognition and diseases that reflect determinants of impaired cognition such as Alzheimer's, Parkinson's and Huntington's. Their drug Sage-718, a novel mechanism of action, targets a protein in the brain, the NMDA receptor, thought to be the brain's coincidence detector designed to link together information that flows from different neural pathways and perhaps correct some of the symptoms causing functional impairment.

@SageBiotech #Alzheimers #Parkinsons #Huntingtons #executivefunction #cognition #neurodegeneration

SageRx.com

Download the transcript here

Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians.

@kempharm #Kempharm $KMPH #ADHD #CNS

KemPharm.com

Listen to the podcast here.

Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians.

@kempharm #Kempharm $KMPH #ADHD #CNS

KemPharm.com

Download the transcript here.